Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2005

View Archived Issues

Weekly BMS-214662 regimen investigated in patients with solid tumors

Alvimopan reduces the duration of postoperative ileus

Rotigotine patch demonstrates safety and efficacy in Parkinson's disease

First European filing for new aerosol inhaler version of Pulmicort

New River seeks to begin clinical trials of NRP-290 for acute pain

Global Pharmatech licenses new anticancer drug

Tilarginine acetate injection studied for cardiogenic shock

In vivo results for QR-440 antiinflammatory compound

Cougar licenses rights to seocalcitol from LEO Pharma

Enrollment under way in phase I study of LAB CGRP for asthma

Novartis extends tender offer for Eon Labs

Oxigene updates vascular targeting programs in ophthalmology

Significant improvements achieved with recombinant leptin in generalized lipodystrophy

Flurizan under clinical evaluation for Alzheimer's disease

Promising results reported for long-term bosentan in PAH associated with scleroderma

Antifungal activity enhancers in early development at Kitasato Institute

Polypeptides for autoimmune diseases emerge from Baxter R&D

Ajinomoto reports ACC inhibitors for diabetes, etc.

New compounds for depression, ADHD, anxiety, etc. disclosed in recent patents

Novel C5a receptor antagonist shows efficacy and stability in a rat model of IBD

FDA accepts for review two Merck vaccine BLAs

MRHA requests more clinical trials for approval of cilansetron for IBS-D

Genta begins submissions for Genasense in U.S., E.U.

Takeda submits NDA for combination type 2 diabetes medication

Nonapprovable letter for PW-2101 for hypertension and angina

Avelox approved for complicated skin and skin structure infections

Avanir completes Neurodex NDA filing

BILR-355-BS shows potent antiviral activity against majority of NNRTI-resistant isolates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...